Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604961 | 0.80 | ACHE (0.50) | KDM4EACHECA1CA2CA4 | |
| SCHEMBL4110681 | 0.77 | KDM4E (0.57) | KDM4EALDH1A1HPGDACHENPC1 | |
| SCHEMBL1512500 | 0.76 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDACHECA1 | |
| SCHEMBL2340155 | 0.74 | KDM4E (0.62) | KDM4EALDH1A1HPGDACHENPC1 | |
| SCHEMBL4226377 | 0.73 | RAB9A (0.57) | KDM4EALDH1A1HPGDACHENPC1 | |
| SCHEMBL31192163 | 0.70 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDACHECA1 | |
| SCHEMBL7980286 | 0.70 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDACHECA1 | |
| SCHEMBL354324 | 0.69 | KDM4E (1.00) | KDM4EALDH1A1HPGDACHECA1 | |
| Methane SCHEMBL28300119 | 0.69 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDACHECA1 | |
| SCHEMBL28040119 | 0.69 | KDM4E (0.63) | KDM4EALDH1A1HPGDACHECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| EP-2358682-A2 | ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010055164-A2 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-05-20 | — | — | WO | disclosed |
| EP-2050452-A1 | indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents | Purdue Research Foundation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-6509344-B1 | A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-21 | — | — | US | disclosed |
| EP-1123099-A4 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1123099-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000021537-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | KDM4E 2120/4885ALDH1A1 2613/4885HPGD 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.